<DOC>
	<DOCNO>NCT01784978</DOCNO>
	<brief_summary>The objective study assess progression-free survival , patient receive rotation sunitinib everolimus versus patient receive sunitinib first line treatment follow everolimus progression occurs .</brief_summary>
	<brief_title>Efficacy Study Sunitinib Everolimus ( Rotational vs Sequential Arm ) Pats . With Clear Cell Renal Cancer</brief_title>
	<detailed_description>This open-label , randomized phase II study investigate feasibility alternate cycle treatment sunitinib everolimus compare sequential treatment sunitinib follow everolimus . The study population consist adult patient ( 18 year old ) clear cell mRCC ( Metastatic Renal Cell Cancer ) receive prior therapy metastatic disease . The purpose study determine progression free survival , feasibility safety profile experimental arm compare standard care . In experimental arm alternating treatment consist repeat cycle 24 week treatment consist 12 week sunitinib 4weeks 2 week , 50 mg pd follow 12 week everolimus 10 mg per day 11 week 1 week patient metastatic clear cell renal cancer . The comparative arm standard regimen sunitinib ( 50 mg pd 4/2 ) progression , follow thereafter everolimus ( 10 mg per day continuously , 11/1 ) progression .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Renal cell carcinoma predominant clear cell component confirm histology . Advanced disease : metastatic AND , suitable resection Male female , age 18 year old ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 1 Low intermediate MSKCC ( Memorial Sloan Kettering Cancer Center ) prognostic risk score , i.e . 2 follow : Karnofsky performance status ( &lt; 80 % ) Low serum hemoglobin ( ≤ 13 g/dL male ≤ 11.5 g/dL female ) High correct serum calcium ( ≥ 10 mg/dL ) Target and/or nontarget lesion accord RECIST 1.1 ( Response Evaluation Criteria Solid Tumors ) Expected survival least 3 month . No prior systemic treatment . But adjuvant treatment ok stop ≥ 24 month Adequate bone marrow function show : Adequate liver function show : Adequate renal function show serum creatinine ≤ 1.5 x ULN ( upper limit normal ) Left ventricular ejection fraction ≥55 % gated cardiac blood pool scan , normal leave ventricular function fractional shortening echocardiogram ( accord institutional limit ) . SBP ( systolic blood pressure ) ≤140mmHg DBP ( diastolic blood pressure ) 90mmHg ( acceptable initiate antihypertensive treatment prior registration achieve goal ) . Able commence treatment within 7 day registration . Willing able comply followup protocol requirement . Written inform consent Prior treatment VEGFtargeting agent multikinase inhibitor mTORtargeting agent Active central nervous system metastasis . Other malignancy diagnose within last 5 year , except follow adequately treat : superficial squamous cell carcinoma basal cell carcinoma skin , superficial bladder cancer ( T1 G1 T1 G2 ) , stage 1 cervical cancer . Treatment investigational agent last 4 w. Known HIV positive . Evidence chronic hepatitis due hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Clinically significant heart disease ( NYHA Class III IV ) History hypertension require hospitalization . Other serious illness , Immunotherapy chemotherapy last 4 w ( 6 week nitrosoureas ) Major surgery last 4 w , plan next 6 w Radiation therapy last 2 w , plan next 6 w NCI CTCAE ( Common Toxicity Criteria Adverse Effects ) version 4.0 grade 3 bad hemorrhage last 4 w. Any follow last year : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Preexisting thyroid abnormality thyroid function maintain normal range medication . Ongoing cardiac dysrhythmias NCI CTCAE version 4.0 grade ≥2 , atrial fibrillation grade , prolongation correct QT interval ( QTc ) &gt; 450 msec male &gt; 470 msec female Uncontrolled diabetes define fast serum glucose &gt; 1.5 X ULN . Pregnancy , lactation . Inadequate contraception . Known allergy hypersensitivity everolimus , sunitinib iodine . Medical psychiatric condition compromise patient 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>renal</keyword>
	<keyword>metastatic</keyword>
	<keyword>clear</keyword>
	<keyword>cell</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Alternating</keyword>
</DOC>